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ABSTRACT
The recent growth of medicine sales online represents 
a major disruption to pharmacy markets, with COVID-19 
encouraging this trend further. While e- pharmacy 
businesses were initially the preserve of high- income 
countries, in the past decade they have been growing 
rapidly in low- income and middle- income countries 
(LMICs). Public health concerns associated with e- 
pharmacy include the sale of prescription- only medicines 
without a prescription and the sale of substandard and 
falsified medicines. There are also non- health- related risks 
such as consumer fraud and lack of data privacy. However, 
e- pharmacy may also have the potential to improve access 
to medicines. Drawing on existing literature and a set of 
key informant interviews in Kenya, Nigeria and India, we 
examine the e- pharmacy regulatory systems in LMICs. 
None of the study countries had yet enacted a regulatory 
framework specific to e- pharmacy. Key regulatory 
challenges included the lack of consensus on regulatory 
models, lack of regulatory capacity, regulating sales 
across borders and risks of over- regulation. However, e- 
pharmacy also presents opportunities to enhance medicine 
regulation—through consolidation in the sector, and the 
traceability and transparency that online records offer. The 
regulatory process needs to be adapted to keep pace with 
this dynamic landscape and exploit these possibilities. This 
will require exploration of a range of innovative regulatory 
options, collaboration with larger, more compliant 
businesses, and engagement with global regulatory bodies. 
A key first step must be ensuring that national regulators 
are equipped with the necessary awareness and technical 
expertise to actively oversee this e- pharmacy activity.
INTRODUCTION
The sale of medicines over the internet repre-
sents a major disruption to pharmacy markets 
across the globe. E- pharmacy has proliferated 
since the first online sales to consumers in the 
late 1990s. The global e- pharmacy market is 
currently worth around US$81.6 billion, and 
expected to grow to US$244 billion by 2027.1 
While initially the preserve of high- income 
countries (HICs), in the past decade it has 
been growing rapidly in low- income and 
middle- income country (LMIC) settings2 3; 
for example India’s share of the global market 
is US$9.3 billion with a compound annual 
growth rate of 18%.4
Summary box
 ► The e- pharmacy sector has been rapidly growing in 
low- income and middle- income countries over the 
past decade, with the COVID-19 pandemic encour-
aging a further surge in online sales, and an associ-
ated rise in cybercrime.
 ► Online medicine sales are linked to both public 
health concerns, such as sale of prescription- only 
medicines without a prescription, and sale of sub-
standard and falsified medicines; and cyber- security 
concerns, including consumer fraud and lack of data 
privacy.
 ► E- pharmacy may also present opportunities for en-
hancing access to medicines, particularly for those 
requiring regular medication for chronic conditions, 
or with problems accessing traditional pharmacy 
services.
 ► Regulation of the sector has not kept pace with these 
rapidly evolving, dynamic markets which operate 
with ease across national boundaries, and present 
distinct regulatory challenges.
 ► Regulators need to pay greater attention to this 
sector, ensure they have the technical expertise to 
supervise it and adapt regulatory process to take 
advantage of the opportunities e- pharmacy provides 
for enhancing traceability and transparency of med-
icine sales.
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Lockdowns and self- isolation due to COVID-19 have 
further catalysed online medicine sales. Key market 
players in India have reported sales surges of 100%–
200%.5 There have also been reports of a shift to more 
elderly customers with chronic conditions, and these new 
trends are expected to continue, at least to some degree, 
even after the pandemic subsides.
The rapid expansion of the e- pharmacy market has been 
largely uncontrolled, and accompanied by significant public 
health concerns, such as sale of prescription- only medicines 
(POMs) without a prescription, and inadequate informa-
tion provision to patients.6–8 In addition, non- health- related 
risks include consumer fraud and lack of data privacy (ibid). 
However, e- pharmacy also presents potential opportunities 
for enhancing access to medicines. Purchasing medicines 
online can be quick, simple, convenient and private, and, 
as internet and smart phone penetration increases, e- phar-
macy has the potential to improve access for the disabled, 
the elderly, and those living in rural areas.9
The regulatory environment within which e- pharmacy 
operates will be crucial in managing how these risks and 
opportunities play out. In this paper we explore e- phar-
macy regulation in LMICs, drawing on a set of 18 key infor-
mant interviews we conducted in Kenya, India and Nigeria, 
as well as relevant literature. The interviews took place 
between September and December 2018 with the chief 
executive officers of e- pharmacies, health policymakers and 
senior regulatory officials, and were analysed thematically. 
We begin by describing the e- pharmacy business models, 
key risks to consumers and current regulatory responses in 
the above three countries, before turning to the challenges 
and opportunities these pose for effective regulation. We 
conclude by proposing next steps for policy and research.
E-PHARMACY BUSINESS MODELS
Interviewees reported that e- pharmacies can be provider- 
facing (business to business selling) or consumer- facing 
(business to consumer selling). They are predominately 
for- profit, with a few social enterprises. Most are consumer- 
facing, with two main business models: establishments that 
stock medicines and supply them via e- orders (inventory 
model), and those that serve as a link between consumers 
and existing physical pharmacies, often through a mobile 
phone application (marketplace model). The inventory 
model can be further divided into businesses that operate 
purely online, and hybrid models which operate both 
brick- and- mortar and online pharmacies. In response to 
COVID-19, many brick- and- mortar pharmacy chains have 
developed online platforms, general online retailers are 
increasingly stocking medicines, and new providers are also 
entering the market.
RISKS TO CONSUMERS
Dangers from inappropriate medicine provision
The main risks to consumers identified in the litera-
ture relate to the sale of medicines, particularly POMs, 
which can easily be ordered without a prescription from 
many e- pharmacies.10 11 This includes antibiotics, which 
if used incorrectly can contribute to antimicrobial resist-
ance, declared a ‘global health security emergency’ by 
WHO.12 Another key concern is narcotic sales, which are 
associated with controlled prescription drug (CPD) use 
disorders. Well described in HICs,13 these are a growing 
phenomenon in LMICs; non- medicinal use of prescrip-
tion opioids, over- the- counter cough syrups containing 
opioids and amphetamines have all been reported across 
Africa and Asia.14 CPD use disorders can lead to devas-
tating effects, including cardiovascular complications, 
deadly overdose and severe mental ill- health (ibid). 
Further, e- pharmacy is argued to have fuelled the sale 
of falsified medicines,15 reflecting the trade’s anonymity 
and global reach. When the quantity of active ingredient 
falls outside the therapeutic range, falsified medicines 
can lead to treatment failure and even death. Addition-
ally, the inclusion of harmful ingredients such as boric 
acid, toxic paint, and antifreeze can be fatal.16
In some cases, e- pharmacies employ doctors to write 
prescriptions, though our key informants reported that 
this was often without taking any patient history or even 
personal details. There is also disquiet relating to the 
storage, handling and delivery of medicines that require 
an unbroken cold chain. At a broader level, there is said 
to be a general lack of clinical oversight within many 
e- pharmacies.
Data security and cybercrime
Data security and patient confidentiality are important 
concerns. Many sites do not secure customers’ informa-
tion, post- purchase emails often contain unencrypted 
links to customer information and online transactions 
are inadequately protected.17 Such site vulnerabilities 
can lead to consumer fraud and inadequate data protec-
tion. Moreover, cybercrime related to the COVID-19 
pandemic is reported to be extremely dynamic and 
growing, including online sales of bogus cures, counter-
feit test kits and non- delivery scams.18 19
THE REGULATORY RESPONSE
Existing regulatory systems and agencies in Kenya, 
Nigeria and India have been slow to adapt to e- pharmacy. 
Although key informants in all three countries viewed 
effective regulation as a priority, at the time of writing, 
none had enacted a specific regulatory framework. Better 
regulation is hindered by confusion over regulatory 
responsibilities, particularly reflecting where e- pharmacy 
falls between the jurisdictions of health and e- commerce.
The countries are at different stages in working 
towards e- pharmacy regulation (table 1). The Kenyan 
retail pharmaceutical sector is regulated by the Pharmacy 
and Poisons Act (Cap 244 of Kenyan Laws), which pre- 
dates Independence and is viewed as outdated, despite 
numerous amendments over the years.20 At present, 
there are no statutory provisions that directly govern 
e- pharmacy. The drug regulatory authority, the Pharmacy 
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and Poisons Board, was navigating this gap by using an 
informal system whereby e- pharmacies sought a ‘letter 
of no objection’ to operate and has recently introduced 
a basic e- pharmacy registration process. In Nigeria, the 
body responsible for licensing pharmacies, the Pharmacy 
Council of Nigeria, is said to have developed rules to 
guide the regulatory process for e- pharmacy in 2016, but 
they have not yet been made public.
In India, medicine sales fall under the Drugs and 
Cosmetics Act (1940), the Drugs and Cosmetic Rules 
(1945) and the Pharmacy Act (1948).21 In 2015 the 
Drug Controller of India alerted e- pharmacies that they 
must comply with this legislation, yet the following year 
acknowledged that it was inadequate and incompat-
ible with e- pharmacy. In 2016, the Federation of Indian 
Chambers of Commerce and Industry introduced a ‘self- 
regulation code of conduct’ for e- pharmacy.22 Later that 
year, a subcommittee of the Drugs Consultative Committee 
examined the issue, leading to amendments to the 1945 
Rules which were released in draft form in August 2018, 
but not notified. The Draft Rules require e- pharmacies 
to register through a Central Licensing Authority, and 
include details of medicines excluded from online sales, 
for example, narcotics; inspection procedures (bi- annual 
carried out by the Central Licensing Authority); adver-
tising constraints (no direct- to- consumer advertising); 
and record keeping requirements. These Rules have 
been pending approval for over 2 years.
Within healthcare more broadly, there is legislation 
governing personal health records, such as the National 
Health Act, 2014, in Nigeria,23 and the Electronic Health 
Records Standards in India,24 but nothing specifically 
aimed at online medicine sales. In Kenya, the Health Act 
2017 allows for the establishment of a body to regulate 
health products and technologies.25 There is potential 
for this to cover e- pharmacies, but it has not yet been 
used. Regulation of information technology and e- com-
merce is also evolving rapidly, further stimulated recently 
by increased use of digital technologies during the 
COVID-19 pandemic. Examples of potentially relevant 
legislation include India’s Information Technology Act, 
2000, and proposed Personal Data Protection Bill, and 
Kenya’s Information and Communications Act 2013. In 
Nigeria, the National Information Technology Develop-
ment Agency (NITDA) Act (2007) through section 6 (c) 
provides for NITDA to develop guidelines for electronic 
governance and to monitor the use of electronic data 
interchange, where the use of electronic communication 
will improve the exchange of information.26
The discrepancy between the strict regulations (on 
paper) for brick- and- mortar pharmacies and the absence 
of regulation for e- pharmacies has been the source of 
considerable grievance for brick- and- mortar pharmacy 
owners who feel this does not represent a level playing 
field, and also have a vested interest in preventing the 
growth of e- pharmacy. This power struggle is most 
evident in India, where the Tamil Nadu Chemist and 
Druggist Association has (successfully) taken legal action 
against e- pharmacy firms, and the All India Association 
of Chemists and Druggists has organised nationwide 
Table 1 Overview of regulation of brick- and- mortar and e- pharmacies in India, Kenya and Nigeria
Relevant regulatory agencies; 
roles and responsibilities
Regulation of brick- and- mortar 
pharmacies Regulation of e- pharmacies
India  ► Central Drugs Standard 
Control Organisation
 ► State Drug Regulatory 
Authorities
 ► Pharmacy Council of India
 ► Pharmacy Act, 1948
 ► Drugs and Cosmetic Act, 1940
 ► The Drugs and Cosmetic Rules, 1945
 ► The Pharmacy Practice Regulations, 
2015
 ► Drugs and Magic Remedies Act, 1954 
(advertising)
 ► Drugs and Cosmetic 
(Amendment) Rules, 2018 
(pending)
 ► Federation of Indian Chambers 
of Commerce and Industry, self- 
regulation through voluntary 
code of conduct, 2016
Kenya Pharmacy and Poisons Board 
(PPB)
Pharmacy and Poisons Act (Cap 244 of 
Kenyan Laws)
Informal letter of no objection from 
PPB; basic registration process 
recently introduced
Nigeria  ► Pharmacists Council of Nigeria
 ► National Agency for Food 
and Drug Administration and 
Control
 ► Pharmacists Council of Nigeria Decree 
1992 (Decree No. 91)
 ► Poison and Pharmacy Act (Cap 535), 
1946 and 1947
 ► National Agency for Food and Drug 
Administration and Control Decree 
1993 (Decree No. 15) and Amendment 
Decree 1999 (Decree No. 19)
 ► Drugs and Unwholesome Processed 
Food Decree 1999 (Decree No. 25)
 ► Pharmacists Council of Nigeria 
(Disciplinary Tribunal Rules) 2000
Unpublished regulations for e- 
pharmacy since 2016
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strikes in protest at e- pharmacy operation.27 In July 2020, 
legal objections from almost 850 000 brick- and- mortar 
pharmacies were successful in overturning the inclusion 
of an e- pharmacy portal in the government’s COVID-19 
contact- tracing app.28
REGULATORY CHALLENGES
We present four key challenges to regulating e- phar-
macy, related to lack of consensus on regulatory models, 
capacity, regulating cross border trade, and risks of over- 
regulation.
Lack of consensus on regulatory models
Lower- income countries might consider looking to the 
regulatory experience of their higher income counter-
parts, which have been grappling with e- pharmacy for 
longer.29 However, there is no consensus in upper- middle 
and HICs on appropriate regulations. For example, in 
Thailand it is illegal to sell medicines online; whereas in 
the UK and Germany e- pharmacies are regulated as an 
extension of physical pharmacies and incorporated into 
existing regulatory frameworks. While the UK has a rela-
tively permissive environment, Germany is more restric-
tive, only allowing the e- pharmacy sales from a few select 
countries.
Arguably one of the largest challenges facing HICs is 
the plethora of illegal or rogue e- pharmacies that operate 
without licensure, offer POMs without a prescription, and 
sell counterfeit medicines and goods. A small number of 
criminal gangs own thousands of ever- renewing bogus 
pharmacy websites.30 To address this challenge, several 
HICs have placed emphasis on verification systems 
to identify legitimate e- pharmacies, through the ‘EU 
common logo’, US Digital Pharmacy Accreditation and 
Canada’s Canadian International Pharmacy Association 
(CIPA) certification mark. To receive accreditation US 
e- pharmacies must apply for a ‘.pharmacy’ domain, a 
simple way to signal quality to customers through the web 
address. Further, search engines such as Google, Yahoo! 
and Bing now require a ‘.pharmacy’ domain in order 
to use their advertising services. Despite these develop-
ments, most HIC governments would admit to facing 
major challenges in regulatory compliance.
Regulatory capacity and governance
While there are well- established legal frameworks for 
brick- and mortar pharmacies in LMICs (table 1), in 
practice they are often staffed by unqualified personnel, 
over- the- counter sale of POMs is rampant, history taking 
and information provision is inadequate and clinically 
inappropriate medicines are provided, including misuse 
of antibiotics.31–33 More generally, governance in the 
pharmacy sector has been identified as poor, with high 
levels of corruption treated as normal.34–36 Regulatory 
agencies tasked with addressing these problems are 
under- staffed and overburdened. Against this backdrop, 
the added burden of regulating e- pharmacy is daunting. 
Traditional pharmaceutical regulators lack the skills to 
monitor online transactions and their complex links with 
shipping, online advertising and payment services; and 
lack the power and resources to control large companies. 
Substantial capacity building and resource commitment 
are identified as necessary but are not yet forthcoming.
Regulating across borders
Added to these problems is the challenge of using 
national regulatory frameworks to control a market 
that operates with ease across geographical bounda-
ries. In the study countries, restrictions on imports for 
personal use vary. In India, a doctor’s prescription should 
accompany personal shipments; in Kenya, import of up 
to 3 months’ supply of prescription drugs is permitted 
subject to approval by the Health Ministry; in Nigeria, 
import of medicines requires a license and is also limited 
to 3 months’ supply.37 In practice, these restrictions are 
rarely enforced, with customers easily purchasing from 
other countries. Regulators have no jurisdiction over the 
activities of e- pharmacies outside their national borders, 
which may operate under different systems for medicine 
approvals, marketing procedures and retail pharmacy 
regulation. These challenges are compounded by the 
reach and anonymity of e- pharmacies, and the ease of 
creating new websites and removing old ones.38 39
Despite these challenges, there is no global regulatory 
agency for e- pharmacy, and only limited international 
cooperation. INTERPOL coordinates an annual effort 
entitled ‘Operation Pangea’ to disrupt the sale of falsi-
fied medicines online, seizing 105 million units of medi-
cine and making over 3000 arrests since 2008, but most 
seizures have been in HICs.40 Some independent organ-
isations have set up international verification systems 
eg LegitScript, yet again LMIC coverage remains very 
limited.
Risks of over-regulation
While current regulation is clearly inadequate, there was 
concern among our interviewees that the potential bene-
fits of e- pharmacy could be stifled if future regulations 
were too stringent. Brushwood warns that tough regula-
tion directed towards illegitimate e- pharmacies runs the 
risk of stifling innovation, while doing little to prevent 
inappropriate medicine use.41 He likens this response 
to the ‘war on drugs’ that law enforcement agencies in 
the USA have waged, with limited success; an inadvertent 
effect of trying to protect the public from narcotic drug 
addiction is many patients experiencing uncontrolled 
pain due to limited access to appropriate analgesia.
REGULATORY OPPORTUNITIES
While e- pharmacy presents many regulatory challenges, 
some aspects of its operation may facilitate regulatory 
control. We explore the possibilities of consolidation and 
improved traceability/transparency.
Market consolidation
Currently, pharmacy markets in all three study countries are 
highly fragmented, characterised by a very high number of 
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independent brick- and- mortar retailers and wholesalers. 
The growing e- pharmacy segment offers the potential for 
some degree of consolidation within these markets, leading 
to upstream economies of scale in website platforms, 
procurement and distribution. For example, in India, 
despite numerous start- ups, the online market remains 
dominated by a handful of players including 1mg, MedLife, 
Netmeds, Pharmeasy, Myra and CareOnGO. Such market 
concentration could improve the regulatory situation. First, 
larger companies may be less costly to regulate than the 
many small individual brick- and- mortar pharmacies, as they 
are easier to identify and much of the regulatory activity can 
take place through a central headquarters. Second, systems 
of internal quality control and self- regulation may be more 
likely in order to preserve brand identity. For example, 
some e- pharmacies in Kenya have instituted their own rules 
and safety checks, such as mechanisms to ensure POM sales 
are based on a valid prescription. A social enterprise report-
edly only works with registered pharmacies that employ a 
registered pharmacist and sends them reminders when 
licenses need to be renewed. Such consolidation may also 
enhance control over procurement, potentially improving 
medicine quality. Finally, economies of scale and greater 
transparency of price comparisons42 could reduce prices, as 
it has in other sectors43; many e- pharmacies certainly claim 
to offer cheaper medicines than brick- and- mortar pharma-
cies,44 although there is currently little research evidence to 
confirm this.
Traceability and transparency
In all three countries, the potential for e- pharmacy 
to improve the traceability and transparency of medi-
cines sales was emphasised by interviewees. The online 
nature of e- pharmacy transactions is believed to allow 
for greater transparency, if relevant records are made 
available to regulators.42 A move towards e- prescrip-
tions could enable prescription analysis, whereby regu-
lators could verify authenticity of prescriptions and 
gather information regarding appropriateness of medi-
cine use. Further, regulators could assess compliance 
with some regulations using online mystery shoppers, 
saving time and financial resources. The traceability of 
transactions online would allow for identification of 
details such as batch number and expiry dates, which 
in turn could enable the possibility of tracking coun-
terfeit medicines and allow for quicker recall of medi-
cines in the event of adverse drug reactions. The use 
of blockchain solutions may enable such possibilities, 
providing each medicine with a unique identification 
code that can be tracked at every stage of the distri-
bution chain from manufacture to end- user, using 
tamper- proof encryption technologies.
NEXT STEPS: AN AGENDA FOR E-PHARMACY POLICY AND 
RESEARCH
There is an opportunity for LMICs to use regulation to 
shape the e- pharmacy sector while it is still emerging, 
and, if appropriate, even encourage its expansion. 
This opportunity may be amplified by the COVID-19 
pandemic, with health at the forefront of public and 
political consciousness, and online medicine sales (and 
associated scams) soaring. In fact we could be presented 
with a ‘window of opportunity’ for policy change, with 
the identification of the problem, the development of 
strategies to address it and the political appetite to do 
so beginning to converge.45 Advances in digital health 
governance, such as the Indian National Digital Health 
Mission and Telemedicine Practice Guidelines released 
in the context of COVID-19 in 2020, present an opportu-
nity for principles and processes relevant for e- pharmacy 
regulation to be better articulated.46 47
Given the dynamism of e- pharmacy markets, coun-
tries should move quickly to address the lack of regula-
tory frameworks. A first step could be for regulators to 
open a dialogue with larger, more compliant businesses, 
and work together to develop best practice guidelines 
and regulatory structures. However, care must be taken 
to guard against regulatory capture and ensure that 
the fundamental principles of pharmacy practice are 
not compromised. Policy options include tightening 
statutory regulation (eg, enhanced licencing, website 
removal), allowing greater flexibility to improve the 
feasibility of compliance (eg, greater prescribing role for 
pharmacists) and improving monitoring (eg, blockchain 
software to track online transactions). Regulation may 
also be enhanced by introducing risk- based approaches, 
whereby resources are focused on those more likely to 
violate the rules.48 Statutory regulation may be combined 
with more persuasive approaches, such as codes of prac-
tice, consumer education, accreditation seals, restricted 
domains such as ‘.pharmacy’ and working with national 
domain name registries and other intermediary busi-
nesses such as credit card companies to restrict rogue 
websites. E- pharmacy could potentially catalyse new regu-
latory thinking across the entire retail pharmacy sector, 
including brick- and- mortar pharmacies.
Achieving these changes requires raising awareness 
among regulators about which firms are operating nation-
ally; the key foreign players used by national residents; 
and common regulatory infringements. Further, regu-
lators need appropriate technical expertise, requiring 
both training of existing staff and recruitment of infor-
mation technology and e- commerce specialists. Regu-
lating across borders will require a coordinated, global 
response, including enhanced international surveillance. 
Organisations working in this domain should look to 
expand their initiatives further among LMICs and share 
expertise with national regulators. Finally, inter- country 
learning through the exchange of lessons and best prac-
tices should be encouraged.
Research on e- pharmacy to support these develop-
ments remains limited. Moving forward, we propose 
a research agenda that (1) addresses the perfor-
mance of e- pharmacies, in terms of quality of service 
provision, prices and equity of access; (2) considers 
how the interests and power of stakeholders in this 
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market influence regulatory systems development and 
enforcement; (3) tracks the regulatory response and 
evaluates its effectiveness; and (4) supports the devel-
opment of viable technologies to support the enforce-
ment of regulatory frameworks.
CONCLUSION
E- pharmacy is rapidly growing in LMICs and this 
trend is likely to continue, amplified by COVID-19 and 
expanding e- commerce ecosystems. Under- regulated 
e- pharmacy markets pose serious threats to public 
health through misuse of medicines; yet the oppor-
tunities e- pharmacy provides to increase access and 
quality should not be overlooked. Current regulations 
have not kept pace with technological innovation and 
HICs are yet to develop effective models for LMICs to 
draw on, with the latter still grappling with endemic 
regulatory infringement in brick- and- mortar phar-
macies. It will be important for rigorous research to 
accompany the growth of this industry and the regula-
tory response as it evolves.
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